Konig Heiko, Levis Mark
Johns Hopkins University, Baltimore, MD, USA.
Curr Hematol Malig Rep. 2014 Jun;9(2):118-27. doi: 10.1007/s11899-014-0198-1.
The prognosis for patients with acute myeloid leukemia (AML) is determined to a large degree by the biology of the leukemic cell. In recent years, the identification and characterization of genetic aberrations has vastly improved our understanding of the pathogenesis of AML. In contrast, however, there has been a lack of clinically meaningful therapeutic advances. The same chemotherapeutic strategies have been applied to AML for several decades now, and while these regimens are effective in inducing remission, most patients relapse within months after initial treatment. Hence, there is an urgent need for novel therapies. We review herein a number of lines of laboratory and clinical trial data supporting the clinical value of targeted treatment approaches that will likely result in improved outcomes for patients with AML.
急性髓系白血病（AML）患者的预后在很大程度上取决于白血病细胞的生物学特性。近年来，基因畸变的识别与特征分析极大地增进了我们对AML发病机制的理解。然而，相比之下，临床上有意义的治疗进展却较为匮乏。相同的化疗策略已应用于AML数十年，虽然这些方案在诱导缓解方面有效，但大多数患者在初始治疗后的数月内就会复发。因此，迫切需要新的治疗方法。我们在此回顾一系列实验室和临床试验数据，这些数据支持靶向治疗方法的临床价值，而靶向治疗方法可能会改善AML患者的治疗效果。
